C4 THERAPEUTICS INC (CCCC) Stock News

NASDAQ:CCCC - Nasdaq - US12529R1077 - Common Stock - Currency: USD

2.5 -0.08 (-3.1%)

After market: 2.4626 -0.04 (-1.5%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CCCC Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Benzinga - Mentions: USPH EBS HAE ECOR ...

12 Health Care Stocks Moving In Thursday's Intraday Session

2 days ago - By: The Motley Fool

CCCC Revenue Drops 46%

2 days ago - By: Zacks Investment Research - Mentions: DARE

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

2 days ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

8 days ago - By: Zacks Investment Research - Mentions: OCGN

Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: NTLA

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

3 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

3 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

3 months ago - By: Zacks Investment Research - Mentions: SAGE

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates

5 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

5 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

6 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics to Participate in Upcoming March Investor Conferences

7 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

7 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

7 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

7 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

8 months ago - By: Benzinga - Mentions: JBL MU PPG S ...

AT&T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday

8 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

8 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

9 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

9 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

9 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

9 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

9 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting

9 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

9 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

9 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

9 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10 months ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

a year ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

a year ago - By: C4 Therapeutics, Inc.

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024